NephroGenex, Inc. (NASDAQ: NRX) is an innovator in the development of drugs to treat kidney disease with a first indication in diabetic nephropathy. It has been pioneering the development of PYRIDORIN (pyridoxamine dihydrochloride), a late stage compound to treat the one-third of diabetics with this slow-developing but potentially deadly disease. The drug is designed to scavenge a broad range of the pathogenic oxidative chemistries that are elevated in diabetics and cause kidney damage in order to slow/stabilize the progression of end-stage renal disease. For more information, visit the company’s website at www.nephrogenex.com.